News 27.04.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the...
News 17.04.2025 Zurich/Schlieren ZH - Researchers at the University of Zurich are developing a urine test for the diagnosis of prostate cancer. To advance the project and organize mass screening, they have founded the spin-off ONTRACK Biomedical. Biochemist Irina Banzola and urologist Daniel Eberli of the University of Zurich (UZH) have developed a...
News 15.04.2025 Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial performance for the first three months of 2025. Revenue from Direct MagnetOs product sales rose 79% in the first three months of 2025, to USD...
News 14.04.2025 Switzerland – 14 April 2025 – CUTISS, a late-stage clinical biotech at the forefront of tissue therapeutics and regenerative medicine, today announced a strategic partnership with Tecan, a global leader in the development, production, and distribution of automation solutions for the life sciences and diagnostics sector. This collaboration marks a...
News 10.04.2025 Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2...